Lung Cancer

Conservative radio host Rush Limbaugh, 70, has died after receiving an advanced lung cancer diagnosis one year ago.

The FDA approved Cosela, a first-in-its-class therapy to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer.

CURE will host a webinar, sponsored by Amgen, in which panelists from several cancer organizations will discuss ways to improve awareness around biomarker testing, improve coordination of care for patients with lung cancer and remove barriers to access to care.

The Food and Drug Administration has granted an accelerated approval to Tepmetko for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose disease harbors mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

Treatment with sotorasib induced a 6.8-month median progression-free survival in patients with KRAS G12C–mutated advanced non-small cell lung cancer.

Recent study results demonstrated that an at-home prehabilitation program may improve surgical outcomes in patients with lung cancer.

A survey conducted by the LUNGevity Foundation determined that 96% of patients with lung cancer felt that they were concerned about the COVID-19 pandemic affecting their treatment.

New study results demonstrate that patients with lung cancer have experienced more worries and general distress during the COVID-19 pandemic compared to other patients with cancer.

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for January 2021.

Dustin Diamond, known best for his role as “Screech” in “Saved by the Bell,” has died after receiving a stage 4 lung cancer diagnosis a few weeks ago.

Despite offering an increased number of services to patients, the decrease in funding as a result of the pandemic has put a strain on patient advocacy and support organizations around the world, leaving many, particularly those that specialize in the support of patients with lung cancer, in urgent need of financial support to continue to meet the increased need.

Keytruda monotherapy continued to significantly improve overall and progression-free survival in patients with previously treated, PD-L1–positive advanced non-small cell lung cancer.

Onivyde may offer patients with small cell lung cancer whose disease has progressed after initial chemotherapy a new treatment option, according to updated study results.

Treatment with immuno-oncology therapies induces better responses in younger patients with small cell lung cancer, compared to older patients.

Though there are currently few approved treatments for advanced, pre-treated small cell lung cancer (SCLC), this patient population may have a safe and effective new option in apatinib, according to updated data from a prospective phase 2 study.

Treatment with Opdivo (nivolumab) in combination with the novel therapy BMS-986012 demonstrated a median overall survival of 18.7 months and a median progression-free survival of 2.1 months among a group of patients with relapsed/refractory small cell lung cancer.

In a survey conducted by the Cancer Support Community, 33% of patients with lung cancer reported they were somewhat or not at all involved in the decision-making process, and 66% were not as knowledgeable about their treatment options as needed to make this decision.

Biomarkers play an important role in treatment decisions of many tumors, but in lung cancer they are a deciding factor between which immunotherapy is the best option.

Here is a list of some recent trials that launched within the cancer space in January.

Tecentriq with carboplatin and etoposide led to a median overall survival rate of 12.3 months versus 10.3 months in those assigned placebo, carboplatin and etoposide, although the death rate was high at a median follow-up of 22.9 months.

Findings from a study focused on patient-reported experiences, found that aching joints, aching muscles and fatigue were more common than initially found in clinical trials.

Patients with ALK-positive non-small-cell lung cancer who received Lorbrena reported better quality of life and had longer progression-free survival than patients who received Xalkori.

The FDA based its decision on data that demonstrated that the novel therapy in combination with Tecentriq induced a higher overall response to therapy compared to Tecentriq alone in patients with PD-L1-positive non-small cell lung cancer.

The FDA granted a priority review to the supplemental new drug application for Lorbrena for the firstline treatment of ALK-positive metastatic non-small cell lung cancer.

The company has withdrawn the small cell lung cancer indication for Opdivo (nivolumab) based on discussions with the FDA, particularly focused on post-market studies that missed their primary endpoints of overall survival.